CC
DGX icon

Cypress Capital’s Quest Diagnostics DGX Stock Holding History

Cypress Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20,551
Closed -$2.73M – 110
2022
Q2 		$2.73M Hold
20,551
– – 0.39% 48
2022
Q1 		$2.81M Hold
20,551
– – 0.34% 50
2021
Q4 		$3.56M Hold
20,551
– – 0.41% 45
2021
Q3 		$2.99M Buy
+20,551
New +$3.01M 0.38% 44

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cypress Capital's DGX Position: Q3 2022 in Review

Cypress Capital sold out of Quest Diagnostics (DGX) in Q3 2022, closing a stake of 20,551 shares — an estimated $2.73M sold.

Cypress Capital first reported a position in DGX in Q3 2021 and held it in 4 quarters. The position peaked at $3.56M in Q4 2021. 808 funds tracked by Wall St. Rank hold DGX as of Q3 2022.

  • Cypress Capital reported no remaining Quest Diagnostics position as of Q3 2022 after selling out during the quarter.
  • Cypress Capital sold 20,551 Quest Diagnostics shares in Q3 2022, an estimated $2.73M.
  • Cypress Capital first reported a position in Quest Diagnostics in Q3 2021 and held it in 4 quarters.
  • Cypress Capital's Quest Diagnostics position peaked at $3.56M in Q4 2021.
  • 808 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2022.

Based on Cypress Capital's 13F filing for Q3 2022, filed 1 Feb 2023.